WallStSmart

Clearpoint Neuro Inc (CLPT)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 88696% more annual revenue ($37.54B vs $42.28M). MDT leads profitability with a 13.9% profit margin vs -81.8%. CLPT appears more attractively valued with a PEG of 0.61. MDT earns a higher WallStSmart Score of 68/100 (B-).

CLPT

Avoid

33

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 6.3Quality: 5.0
Piotroski: 4/9Altman Z: -2.62

MDT

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CLPTUndervalued (+11.7%)

Margin of Safety

+11.7%

Fair Value

$15.14

Current Price

$13.72

$1.42 discount

UndervaluedFair: $15.14Overvalued
MDTUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$94.43

Current Price

$90.96

$3.47 discount

UndervaluedFair: $94.43Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CLPT2 strengths · Avg: 8.0/10
PEG RatioValuation
0.618/10

Growing faster than its price suggests

Revenue GrowthGrowth
18.1%8/10

18.1% revenue growth

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$116.35B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

EPS GrowthGrowth
40.7%8/10

Earnings expanding 40.7% YoY

Free Cash FlowQuality
$1.29B8/10

Generating 1.3B in free cash flow

Areas to Watch

CLPT4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$418.52M3/10

Smaller company, higher risk/reward

Price/BookValuation
39.2x2/10

Trading at 39.2x book value

Return on EquityProfitability
-320.8%2/10

ROE of -320.8% — below average capital efficiency

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CLPT

The strongest argument for CLPT centers on PEG Ratio, Revenue Growth. Revenue growth of 18.1% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.

Bear Case : CLPT

The primary concerns for CLPT are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 5.93 is elevated, increasing financial risk.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

CLPT profiles as a growth stock while MDT is a value play — different risk/reward profiles.

CLPT carries more volatility with a beta of 1.27 — expect wider price swings.

CLPT is growing revenue faster at 18.1% — sustainability is the question.

MDT generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (68/100 vs 33/100) and 13.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Clearpoint Neuro Inc

HEALTHCARE · MEDICAL DEVICES · USA

ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?